Cells from a tumor are shown with a circle pointing out the cancerous cells.

A tumor sample includes a diversity of cell types, including cancer cells and lymphocytes such as T cells.

CREDIT: Roberto Salgado

A new tool predicts immunotherapy responses

Cancer researchers and clinicians regularly use DNA sequencing to analyze cancer cells. A new method now leverages DNA sequencing data to predict patients’ responses to cancer treatment.
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

The more T cells a patient has, the more likely they are to benefit from immunotherapies like checkpoint inhibitor therapy. Therefore, estimating the number of T cells in a tumor sample can help a clinician determine the best cancer-fighting strategy for the patient. 

Many techniques for accurately tracking T cells are inconvenient or are not commonly used by researchers or clinics, but DNA sequencing is a common technique in many labs. Now, researchers have found a way to use DNA sequencing to estimate the number of T cells in a sample.

Described in Nature, the tools T cell receptor excision circle (TREC) and T cell ExTRECT work by parsing a reduction in sequencing depth. By scoring specific sequencing signals, the tool allows researchers to estimate the fraction of T cells in a tumor sample by scanning the whole exome sequencing data.

A lot of researchers sequence DNA, said Robert Bentham, a computational biologist at the University College London Cancer Institute who led the study. “[T cell ExTRECT is] really useful in a lot of cases where you might have only DNA data, and we were just trying to demonstrate, if you want to ask questions about the immune system, you can use this metric.”

Bentham added that many researchers have exome sequencing data left over from previous studies that can be re-analyzed with T cell ExTRECT, which is one of the tool’s biggest strengths. “You can revisit those studies that you have the data for, quickly run this tool, and effectively generate new data. Maybe you’ll be able to look at the immune system in these old data sets, and that could tell you something novel that you hadn’t previously noticed.”

The authors also performed a meta-analysis on tumors treated with immunotherapy and found that T cell ExTRECT predicted the tumor’s response to immunotherapy. The novelty of the finding is not that the presence of T cells predicts the immunotherapy response, but that DNA sequencing could be used to make the prediction.

While T cell ExTRECT has only been tested in the lab and has not yet been proven for the clinic, Eytan Ruppin, a computational biologist from the National Cancer Institute who was not involved in the study, remarked that the tool has broad implications. “The work is — to use a bombastic word — pioneering, potentially groundbreaking because it’s not only a wonderful result, but it’s opened up so many potential real additional research questions and opportunities to explore.”

Reference

Bentham, R. et al. Using DNA sequencing data to quantify T cell fraction and therapy response. Nature  597, 555-560 (2021).

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue